COVID-19 Coagulopathy: Whom to Anticoagulate and How? What Agents to…

Rush University Medical Center

S. Jain

Role of Anticoagulants and Antiplatelet Agents for Patients With COV…

CHEST 2022 Coverage

V. Balasubramanian

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

How do I Recognize and Treat the VEXAS Syndrome?

Cleveland Clinic Rheumatology

P. Grayson

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

FL: How Do I Deal With Relapse?

SOHO Brazil 2024

B. Kahl

ASCO® 2024 Summary: "Treatment of Relapsed HL - Updated Options in L…

2024 ASCO® Annual Meeting Insights Hub

P. Johnson

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Summary of Bispecific Antibodies for Follicular Lymphoma

UChicago Medicine

D. Russler-Germain

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Follicular Lymphoma Management: What Is the New Order?

SOHO 2023 Eleventh Annual Meeting

B. Kahl

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde